JeanMarie Guenot: Pharmaceutical Professional

JeanMarie Guenot has over 20 years of experience as a business executive for several pharmaceutical and biotechnology companies. She has a vast understanding of working with all stages of both private and public companies. She specializes in working with pharmaceutical research and development departments, corporate and commercial development, overall business development, project and alliance management, and venture capital.

One of the things she’s known for is her ability to build or rebuild companies from the ground up. Jeanmarie Guenot has extensive experience and interest in working in the more major therapeutic areas. Most recently, Guenot was recognized for her accomplishments with SKS Ocular.

SKS Ocular is a company that was founded, built, and ran by Guenot. It was a small startup ophthalmic company. Eventually, it gave birth to SKS Ocular 1, the first of five portfolio companies. It focused on dry AMD and ocular drug delivery technologies on linkedin.com. The entire company was focused on helping patients with glaucoma, macular degeneration, and ocular inflammation.

Read more: Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies

Although JeanMarie Guenot is known for her business expertise, she’s also quiet the medical expert. She’s been trained in physical and medicinal chemistry. She focused on quantum mechanical and semi-empirical methods for molecular dynamics, X-ray and NMR refinement, and drug design. She attended both the University of California, where she earned her Ph.D., and The Wharton School at the University of Pennsylvania, where she earned her MBA.

After graduating, Dr. Guenot began her career at Atlas Venture. She was responsible for managing venture capital investments, and she built life science companies, where she operating on a Board of Directors level. Her scientific career didn’t begin until she started working at Hoffmann-La Roche as a principal scientist in preclinical research and development. She and her other team members were trying to discover and develop drugs for metabolic diseases, inflammation, autoimmune diseases and oncology.

Before Hoffmann, Dr. JeanMarie Guenot was Vice President of Corporate and Business Development at PDL BioPharma. While at PDL, Guenot led and negotiated the biggest deal of her career, the Biogen Idec-PDL 50:50. It was an $800 million transaction.

Leave a Reply

Your email address will not be published. Required fields are marked *